Jennison Associates
KRYS icon

Jennison Associates’s Krystal Biotech KRYS Stock Holding History

Jennison Associates’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-33,594
Closed -$6.06M – 615
2025
Q1 		$6.06M Sell
33,594
-269,927
-89% -$45.4M ﹤0.01% 404
2024
Q4 		$47.5M Sell
303,521
-106,536
-26% -$18.9M 0.03% 241
2024
Q3 		$74.6M Sell
410,057
-110,333
-21% -$21.3M 0.05% 163
2024
Q2 		$95.6M Sell
520,390
-150,345
-22% -$25.2M 0.06% 128
2024
Q1 		$119M Sell
670,735
-53,609
-7% -$7.45M 0.08% 103
2023
Q4 		$89.9M Buy
724,344
+383,495
+113% +$42.5M 0.07% 125
2023
Q3 		$39.5M Buy
340,849
+282,583
+485% +$34.5M 0.03% 208
2023
Q2 		$6.84M Buy
+58,266
New +$5.95M 0.01% 401
2022
Q2 		– Sell
-68,309
Closed -$4.54M – 662
2022
Q1 		$4.54M Buy
+68,309
New +$4.26M ﹤0.01% 461

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Jennison Associates's KRYS Position: Q2 2025 in Review

Jennison Associates sold out of Krystal Biotech (KRYS) in Q2 2025, closing a stake of 33,594 shares — an estimated $6.06M sold.

Jennison Associates first reported a position in KRYS in Q1 2022 and held it in 9 quarters. The position peaked at $119M in Q1 2024. 275 funds tracked by Wall St. Rank hold KRYS as of Q2 2025.

  • Jennison Associates reported no remaining Krystal Biotech position as of Q2 2025 after selling out during the quarter.
  • Jennison Associates sold 33,594 Krystal Biotech shares in Q2 2025, an estimated $6.06M.
  • Jennison Associates first reported a position in Krystal Biotech in Q1 2022 and held it in 9 quarters.
  • Jennison Associates's Krystal Biotech position peaked at $119M in Q1 2024.
  • 275 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2025.

Based on Jennison Associates's 13F filing for Q2 2025, filed 1 Aug 2025.